RedHill Biopharma
在场
RedHill Biopharma 是一家在股票代码 RDHL (IL) 下上市的公司。
高管
查看带有其 20 名主要高管的组织结构图
RedHill Biopharma 搜索最多的简介
- Dror Ben-Asher, Chief Executive Officer and Chairman of the Board
- Shmuel Cabilly, Director
- Eric Swenden, Director
创建提醒
跟踪 RedHill Biopharma 的高管变动
药店
RedHill Biopharma 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
RedHill Biopharma 的最新新闻稿
- RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
- RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
- RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
- RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
- RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
- RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
- New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
- RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- RedHill Biopharma Announces First Half 2024 Business Highlights
- RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
- View more press releases Close
通过电子邮件
